Quick answer: Across Delhi-NCR, as of June 2026, Mounjaro costs ₹13,125–₹25,781 per month at MRP and generic semaglutide starts near ₹1,290 per month, available at major chains in Delhi, Gurgaon, Noida, Faridabad and Ghaziabad against prescription. Endocrinologist consults run ₹800–₹1,500 at most NCR hospitals and ₹2,000–₹2,500 for marquee names, where appointment lead times stretch days to weeks. Online prescriptions from registered doctors are legal and valid across the entire NCR.

NCR's real GLP-1 problem isn't supply — it's geography and queues

Delhi-NCR is one healthcare market spread across one megacity and four satellite cities. That sprawl creates the region's signature friction: the doctor you've been told to see is never in your city. The marquee obesity-medicine names cluster in South Delhi (Max Saket, Apollo Sarita Vihar, Sir Ganga Ram) and Gurgaon (Medanta, Fortis FMRI, Artemis, Max Gurgaon). If you live in Noida, Ghaziabad, or Faridabad, every consult is an inter-city expedition on the DND or NH-48 — and GLP-1 titration wants you back every four weeks.

Layer on the queue problem. NCR's most-recommended endocrinologists — the names that come up whenever Mounjaro is discussed in Delhi circles — book out days to weeks in advance; even hospital portals like Max's show first-available OPD and video slots running well into the following week. AIIMS, the budget escape valve, trades money for months.

Demand, meanwhile, is plainly here. In India's largest GLP-1 community dataset, Delhi and Gurgaon together rank second among all cities (behind only Bangalore) — and reporting around Mounjaro becoming India's top-selling drug by value in October 2025 (₹100 crore that month, per Pharmarack) flagged Delhi alongside Mumbai as the biggest sales concentrations.

What treatment costs across NCR (June 2026)

Medication MRPs are national; here's the ladder, then the part that varies — the consult:

Medication (MRP, June 2026): Mounjaro KwikPen ₹13,125 (2.5 mg) → ₹16,406 (5 mg) → ₹20,625 (7.5/10 mg) → ₹25,781 (12.5/15 mg) — see how the dose ladder works. Wegovy from ₹5,660/month at 0.25 mg after Novo's April 2026 cut of up to 48%. Post-patent generic semaglutide (40+ DCGI-approved brands since 20 March 2026): Natco Semanat vials from ~₹1,290/month, Alkem Semasize pens from ~₹1,800, Zydus Semaglyn ~₹2,200, Dr. Reddy's Obeda ~₹4,200, plus Obeda oral tablets (₹99–₹225/tab) from May 2026. Run the math at your dose.

Consults, by sub-city (current Practo/hospital listings):

Sub-city Typical endocrinologist fee Notes
South Delhi (Max Saket, Apollo, SGRH)₹1,200–₹2,000Marquee seniors ₹2,000–2,500; longest waitlists
Gurgaon (Medanta, FMRI, Artemis, Paras, Max)₹1,200–₹2,200Chair-level names around ₹2,200; corporate-panel OPDs busiest evenings
Noida/Ghaziabad (Max, Fortis, Jaypee, Yatharth)₹900–₹1,500Better availability, thinner obesity-medicine bench
West/North Delhi (BLK-Max, Shalimar Bagh)₹1,000–₹1,800—
Standalone endocrine clinics across NCR₹800–₹1,500Often the fastest competent access
AIIMS / government OPDsnominalQueues measured in months; not viable for monthly titration

Add ₹1,800–₹3,000 for the baseline panel (HbA1c, lipids, TSH, liver/kidney function) at NCR private labs — all of which offer home collection.

Start anywhere in NCR — no toll plaza involved

Video consult with a registered physician, labs collected at home in Delhi, Gurgaon, Noida, Faridabad or Ghaziabad, e-prescription valid at any licensed pharmacy.

Where NCR buys

  1. Chains and hospital pharmacies. Apollo Pharmacy and Guardian blanket Delhi and Gurgaon; MedPlus and local cold-chain chemists cover Noida and Ghaziabad. Hospital pharmacies at Max, Medanta, Fortis, Apollo and Artemis dispense against outside prescriptions.
  2. Online cold-chain delivery. Tata 1mg (a Gurgaon company), Apollo 24/7, and PharmEasy deliver pens with ice packs across all five NCR cities; prescription upload mandatory. In May–June, when Delhi crosses 45°C, take delivery in person and refrigerate immediately — a pen left in a gate-house through a loo-wind afternoon is compromised.
  3. The Dubai question. NCR is where "should I just get it from Dubai?" comes up most — a habit from the pre-launch years and Gurgaon's frequent-flyer culture. In 2026 the answer is simply no: carrying undeclared prescription injectables has customs and legality problems, you lose all cold-chain assurance, and DCGI-approved generics at ₹1,290/month plus legal branded options have erased the price motive. The import-agent grey market is also where counterfeit KwikPens circulate. If the seller doesn't demand a prescription, walk away.

Why online supervision fits NCR

The NCR-specific case is the strongest in India on pure logistics: one valid e-prescription works identically in Hauz Khas, DLF Phase 3, and Sector 62 — the patient stops caring which side of the Yamuna or the toll plaza the doctor sits on. India's Telemedicine Practice Guidelines (2020) make video consultations by registered medical practitioners legal nationwide, with prescriptions dispensable at any licensed pharmacy. For the Gurgaon corporate demographic, it also solves the calendar: titration reviews slot between meetings instead of consuming a half-day of leave for a 9-minute OPD interaction you waited 16 days to get.

How Kaivo works if you're in Delhi-NCR

Kaivo is an online, doctor-led GLP-1 program: a video consultation with a registered physician, baseline bloods collected at home anywhere in Delhi, Gurgaon, Noida, Faridabad or Ghaziabad, and an e-prescription valid at whichever licensed pharmacy suits you — Kaivo sells no medication and adds no markup, so brand-versus-generic is decided on your clinical picture and budget. Then structured 4-weekly titration reviews without waitlists, between-visit side-effect support, plateau management, and a maintenance plan from day one. The trial-anchored benchmarks supervision targets: ~15% average loss at 68 weeks on semaglutide 2.4 mg (STEP-1); up to ~20.9% at 72 weeks on tirzepatide (SURMOUNT-1).

Reading from another city? See our guides for Bangalore, Hyderabad, Mumbai and Pune.

Sources

  1. Eli Lilly India — Mounjaro (tirzepatide) KwikPen MRPs by dose (₹13,125 / ₹16,406 / ₹20,625 / ₹25,781 per month), corroborated by May 2026 price trackers; no price cut announced as of June 2026.
  2. Reuters — Novo Nordisk India price reductions of up to 48% (Wegovy) and 36% (Ozempic) effective 1 April 2026; Wegovy 0.25 mg at ₹5,660/month.
  3. CNBC-TV18 / Business Today — post-patent generic semaglutide launches from 20 March 2026: 40+ DCGI-approved brands; Natco Semanat ~₹1,290/month, Alkem Semasize from ~₹1,800, Zydus Semaglyn ~₹2,200; Dr. Reddy's Obeda oral tablets (₹99/₹135/₹225), 20 May 2026.
  4. Pharmarack (via Reuters / CNBC-TV18) — Mounjaro India's top-selling drug by value from October 2025 (~₹100 crore/month); trade reporting placing Delhi alongside Mumbai as the biggest sales concentrations.
  5. Practo and hospital OPD/video booking portals (e.g., Max Healthcare) — NCR endocrinologist consultation fees and first-available-slot observations by sub-city, pulled June 2026; re-verified quarterly.
  6. Kaivo Research — Analysis of 3,001 posts and comments across India's largest GLP-1 community forum, May 2026 (city mention counts).
  7. Telemedicine Practice Guidelines, Board of Governors (MCI) / Ministry of Health & Family Welfare, 25 March 2020.
  8. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). NEJM 2021.
  9. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM 2022.
This article is for education and does not replace medical advice, diagnosis or treatment. GLP-1 medicines are prescription drugs (Schedule H) in India; eligibility is determined only by a registered medical practitioner. Appointment lead times are point-in-time observations (June 2026) and vary by doctor and season. Mounjaro® is a registered trademark of Eli Lilly and Company; Wegovy® and Ozempic® of Novo Nordisk; generic brand names belong to their respective makers. Hospital, clinic and pharmacy names appear solely as neutral statements of availability and pricing — Kaivo is not affiliated with, and does not imply endorsement by, any of them. Medically reviewed by Dr. Harshit Anand, MBBS, MD (Internal Medicine), AIIMS-trained — Physician, Founding Team, Kaivo. Last updated 10 June 2026.